Redox active plasma iron in C282Y/C282Y hemochromatosis

Blood

Volumn 105, Issue 11, 2005, Pages 4527-4531

  Le Lan, Caroline ^b   Loréal, Olivier ^b   Cohen, Tally ^b   Ropert, Martine ^b   Glickstein, Hava ^b   Lainé, Fabrice ^b   Pouchard, Michel ^b   Deugnier, Yves ^b   Le Treut, André ^b   Breuer, William ^b   Cabantchik, Z Ioav ^b   Brissot, Pierre ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; HEMOCHROMATOSIS; HUMAN; IRON BLOOD LEVEL; IRON DEPLETION; IRON OVERLOAD; LIVER FAILURE; LIVER HEMOSIDEROSIS; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

EID: 21144441802     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3468     Document Type: Article

References (28)

1. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40:255-263.
2. Brissot P, Loréal O. Role of non-transferrin-bound iron in the pathogenesis of iron overload and toxicity. Adv Exp Med Biol. 2002;509:45-53.
3. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990;186:1-85.
4. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Rad Biol Med. 1990;9:315-325.
5. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in β-thalassemia patients. Eur J Clin Inv. 2002;32:55-60.
6. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopatic haemochromatosis. Clin Sci. 1985;68:463-467.
7. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792-798.
8. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic haemochromatosis: characterization by high performance liquid chromatography and nuclear resonance spectroscopy. Biol Chem. 1989;264:4417-4422.
9. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest. 2002;32(suppl 1):50-54.
10. Gosriwatana I, Loréal O, Shuli L, Brissot P, Porter J, Hider RC. Quantification of non-transferrin bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273:212-220.
11. Loréal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC. Determination of non-transferrin bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol. 2002;32:727-733.
12. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin bound iron. Anal Biochem. 1990;186:320-323.
13. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound-iron. Anal Biochem. 2001;299:194-202.
14. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-2677.
15. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator. Blood. 2004;104:1504-1510.
16. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2002;32(suppl 1):42-49.
17. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155-1163.
18. Moirand R, Mortaji A, Loréal O, Paillard F, Brissot P, Deugnier Y. Liver iron overload with normal transferrin saturation: a new syndrome. Lancet. 1997;349:95-97.
19. De Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res. 2001;25:1494-1499.
20. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. British J Surg. 1973;60:646-649.
21. Jouanolle AM, Fergelot P, Gandon G, Yaouang J, Le Gall JY, David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997;100:544-547.
22. Barry M, Sherlock S. Measurement of liver-iron concentration in needle-biopsy specimen. Lancet. 1971;2:100-103.
23. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193:533-538.
24. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-362.
25. Brissot P, Deugnier Y, Le Treut A, Regnouard F, Simon M, Bourel M. Ascorbic acid status in idiopathic haemochromatosis. Digestion. 1978;17:479-487.
26. Young IS, Trouton TG, Torney JJ, McMaster D, Callender ME, Trimble ER. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radic Biol Med. 1994;16:393-397.
27. Brissot P, Guyader D, Loréal O, et al. Clinical aspects of hemochromatosis. Transfus Sci. 2000;23:193-200.
28. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-96.